Cargando…
Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer
OBJECTIVES: Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). However, obtaining tumor tissue for mutation analysis is challenging. Here, we aimed to detect serum peptides/prot...
Autores principales: | Yang, Lin, Tang, Chuanhao, Xu, Bin, Wang, Weixia, Li, Jianjie, Li, Xiaoyan, Qin, Haifeng, Gao, Hongjun, He, Kun, Song, Santai, Liu, Xiaoqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457791/ https://www.ncbi.nlm.nih.gov/pubmed/26047516 http://dx.doi.org/10.1371/journal.pone.0128970 |
Ejemplares similares
-
Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer
por: Qu, Lili, et al.
Publicado: (2017) -
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma
por: Wang, Lin, et al.
Publicado: (2017) -
Exploratory study on application of MALDI-TOF-MS to detect serum and urine peptides related to small cell lung carcinoma
por: Lv, Panpan, et al.
Publicado: (2020) -
The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
por: Xu, Jing, et al.
Publicado: (2017) -
The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)